AB307148

Anti-Tafazzin/TAZ 抗体 [EPR26956-58]

Anti-Tafazzin/TAZ antibody [EPR26956-58]

KD Validated
20ul selling size
RabMAb
Recombinant
詳細を見る

Be the first to review this product! Submit a review

(3 Publications)

Rabbit Recombinant Monoclonal Tafazzin / TAZ antibody. Suitable for IP, WB and reacts with Human, Rat, Mouse samples. Cited in 3 publications.

別名を表示する

EFE2, G4.5, TAZ, TAFAZZIN, Tafazzin, Taz, Protein G4.5

5 Images

Supplier Data

Immunoprecipitation - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)

Tafazzin/TAZ was immunoprecipitated from 0.35 mg SW-13 (human adrenal gland; cortex epithelial cell) whole cell lysate 10 ug with ab307148 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab307148 at 1/1000 dilution. VeriBlot for IP secondary antibody (HRP) (ab131366) was used at 1/5000 dilution.

Lane 1 : SW-13 (human adrenal gland; cortex epithelial cell) whole cell lysate 10 ug
Lane 2 : ab307148 IP in SW-13 whole cell lysate
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab307148 in SW-13 whole cell lysate

Blocking and dilution buffer and concentration : 5% NFDM/TBST.

Exposure time : 180 seconds

All lanes:

Immunoprecipitation - Anti-Tafazzin/TAZ antibody [EPR26956-58] (ab307148) at 1/1000 dilution

Lane 1:

SW-13 (human adrenal gland; cortex epithelial cell) whole cell lysate 10 μg

Lane 2:

SW-13 whole cell lysate

Secondary

All lanes:

Immunoprecipitation - VeriBlot for IP Detection Reagent (HRP) (<a href='/products/reagents/veriblot-for-ip-detection-reagent-hrp-ab131366'>ab131366</a>) at 1/5000 dilution

Observed band size: 30 kDa

false

Exposure time: 180s

Supplier Data

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)

Blocking and diluting buffer and concentration : 5% NFDM/TBST Exposure time : 180 seconds

All lanes:

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (ab307148) at 1/1000 dilution

Lane 1:

Human colon cancer tissue lysate 20 μg

Lane 2:

Mouse heart tissue lysate 20 μg

Lane 3:

Mouse skeletal muscle tissue lysate 20 μg

Lane 4:

Rat heart tissue lysate 20 μg

Lane 5:

Rat skeletal muscle tissue lysate 20 μg

Lane 6:

NIH/3T3 (mouse embryonic fibroblast) whole cell lysate 20 μg

Lane 7:

RAW 264.7 (mouse elson murine leukemia virus-induced tumor macrophage) whole cell lysate 20 μg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/50000 dilution

Observed band size: 30 kDa

false

Exposure time: 180s

Supplier Data

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)

Blocking and diluting buffer and concentration : 5% NFDM/TBST Exposure time : Lanes 1, 4 and 5 : 180 seconds, Lanes 2 and 3 : 37 seconds

All lanes:

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (ab307148) at 1/1000 dilution

Lane 1:

SW-13 (human adrenal gland; cortex epithelial cell) non-mitochondrial fraction 20 μg

Lane 2:

SW-13 mitochondria fraction 20 μg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/50000 dilution

Observed band size: 30 kDa

false

Exposure time: 180s

Supplier Data

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)

Blocking and diluting buffer and concentration : 5% NFDM/TBST.

This blot was developed using a high sensitivity ECL substrate. The high-sensitivity ECL substrate used allows for the detection of proteins in the mid-femtogram range.

All lanes:

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (ab307148) at 1/1000 dilution

All lanes:

HEK-293 (human embryonic kidney epithelial cell) whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/50000 dilution

Observed band size: 30 kDa

true

Exposure time: 180s

Supplier Data

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)

Blocking and diluting buffer and concentration : 5% NFDM/TBST.

This blot was developed using a high sensitivity ECL substrate. The high-sensitivity ECL substrate used allows for the detection of proteins in the mid-femtogram range.

All lanes:

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (ab307148) at 1/1000 dilution

Lane 1:

HeLa (human cervical adenocarcinoma epithelial cell) transfected with scrambled siRNA control whole cell lysate at 20 µg

Lane 2:

HeLa transfected with siRNA specifically targeti Tafazzin/TAZ whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/50000 dilution

Observed band size: 30 kDa

true

Exposure time: 180s

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR26956-58

アイソタイプ

IgG

キャリアフリー

交差種

Human, Mouse, Rat

アプリケーション

IP, WB

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/30", "IP-species-notes": "", "FlowCytIntra-species-checked": "notRecommended", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "" }, "Mouse": { "IP-species-checked": "guaranteed", "IP-species-dilution-info": "", "IP-species-notes": "", "FlowCytIntra-species-checked": "notRecommended", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "" }, "Rat": { "IP-species-checked": "guaranteed", "IP-species-dilution-info": "", "IP-species-notes": "", "FlowCytIntra-species-checked": "notRecommended", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "" } } }

style

left-column

製品の詳細

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

出荷温度及び保存条件

製品の状態

Liquid

精製方法

Affinity purification Protein A

バッファー組成

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

出荷温度

Conditional Ambient

短期保存期間

1-2 weeks

短期保存温度

+4°C

長期保存温度

-20°C

分注に関する情報

Upon delivery aliquot

保管に関する情報

Avoid freeze / thaw cycle

style

left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

Tafazzin also known as TAZ is a mitochondrial phospholipid-lysophospholipid transacylase enzyme. It plays a role in the remodeling of cardiolipin a phospholipid found predominantly in the mitochondrial inner membrane. Tafazzin has a molecular mass of approximately 33 kDa. It is expressed in various tissues with higher expression levels found in tissues with high energy demands such as the heart and skeletal muscles.

Biological function summary

Tafazzin is essential for maintaining mitochondrial function and energy production. It is a critical component of the system responsible for cardiolipin metabolism. The enzyme does not work alone; it interacts with other mitochondrial proteins to facilitate the proper composition of cardiolipin species necessary for mitochondrial structural integrity and functionality.

Pathways

Tafazzin serves an important role in various lipid metabolism pathways. It participates in the phospholipid remodeling pathway where it interacts closely with acyltransferases to modify cardiolipin. This interaction is important for mitochondrial processes such as oxidative phosphorylation and energy conversion affecting proteins like cytochrome c oxidase and ATP synthase complex.

Tafazzin mutations are linked to Barth syndrome a rare genetic condition that affects the heart and muscles. This disorder is marked by symptoms including cardiomyopathy muscle weakness and neutropenia. Tafazzin dysfunction interrupts normal cardiolipin remodeling impacting proteins such as cytochrome c which contributes to abnormal energy metabolism seen in the syndrome. Additionally altered Tafazzin activity has connections to mitochondrial dysfunctions observed in some cardiomyopathies.

style

left-column

style

left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

ターゲットの情報

Acyltransferase required to remodel newly synthesized phospholipid cardiolipin (1',3'-bis-[1,2-diacyl-sn-glycero-3-phospho]-glycerol or CL), a key component of the mitochondrial inner membrane, with tissue specific acyl chains necessary for adequate mitochondrial function (PubMed : 12930833, PubMed : 19164547, PubMed : 19700766, PubMed : 26908608, PubMed : 33096711). Its role in cellular physiology is to improve mitochondrial performance (PubMed : 32234310). CL is critical for the coassembly of lipids and proteins in mitochondrial membranes, for instance, remodeling of the acyl groups of CL in the mitochondrial inner membrane affects the assembly and stability of respiratory chain complex IV and its supercomplex forms (By similarity). Catalyzes the transacylation between phospholipids and lysophospholipids, with the highest rate being between phosphatidylcholine (1,2-diacyl-sn-glycero-3-phosphocholine or PC) and CL. Catalyzes both 1-acyl-sn-glycero-3-phosphocholine (lysophosphatidylcholine or LPC) reacylation and PC-CL transacylation, that means, it exchanges acyl groups between CL and PC by a combination of forward and reverse transacylations. Also catalyzes transacylations between other phospholipids such as phosphatidylethanolamine (1,2-diacyl-sn-glycero-3-phosphoethanolamine or PE) and CL, between PC and PE, and between PC and phosphatidate (1,2-diacyl-sn-glycero-3-phosphate or PA), although at lower rate. Not regiospecific, it transfers acyl groups into any of the sn-1 and sn-2 positions of the monolysocardiolipin (MLCL), which is an important prerequisite for uniformity and symmetry in CL acyl distribution. Cannot transacylate dilysocardiolipin (DLCL), thus, the role of MLCL is limited to that of an acyl acceptor. CoA-independent, it can reshuffle molecular species within a single phospholipid class. Redistributes fatty acids between MLCL, CL, and other lipids, which prolongs the half-life of CL. Its action is completely reversible, which allows for cyclic changes, such as fission and fusion or bending and flattening of the membrane. Hence, by contributing to the flexibility of the lipid composition, it plays an important role in the dynamics of mitochondria membranes. Essential for the final stage of spermatogenesis, spermatid individualization (By similarity). Required for the initiation of mitophagy (PubMed : 33096711). Required to ensure progression of spermatocytes through meiosis (By similarity). Exon 7 of human tafazzin is essential for catalysis (PubMed : 19700766).. Isoform 1. Catalyzes the transacylation between lysophosphatidate (such as 1-acyl-sn-glycero-3-phosphate) and phosphatidylglycerol (1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol)) (PubMed : 19700766). Contributes to cardiolipin (1',3'-bis-[1,2-diacyl-sn-glycero-3-phospho]-glycerol or CL) remodeling (PubMed : 12930833, PubMed : 19700766).. Isoform 3. Catalyzes the transacylation between lysophospholipids and phospholipids, and plays a fundamental role in cardiolipin (1',3'-bis-[1,2-diacyl-sn-glycero-3-phospho]-glycerol or CL) metabolism and remodeling.. Isoform 5. Catalytically inactive.. Isoform 7. Catalytically inactive.

See full target information TAFAZZIN

style

left-column

文献 (3)

Recent publications for all applications. Explore the full list and refine your search

Chinese medicine 20:36 PubMed40098188

2025

Chikusetsusaponin IVa targeted YAP as an inhibitor to attenuate liver fibrosis and hepatic stellate cell activation.

Applications

Unspecified application

Species

Unspecified reactive species

Kai Gao,Wei Zhang,Dong Xu,Meina Zhao,Xingru Tao,Yunyang Lu,Jingwen Wang

Neoplasia (New York, N.Y.) 60:101102 PubMed39674114

2024

USP20 mediates malignant phenotypic changes in bladder cancer through direct interactions with YAP1.

Applications

Unspecified application

Species

Unspecified reactive species

Wensun Chen,Siqi Wu,Yifan Chen,Weijian Li,Yiqing Cao,Yingchun Liang,Xiyu Dai,Xinan Chen,Yilin Chen,Tian Chen,Shenghua Liu,Chen Yang,Haowen Jiang

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11:e2309133 PubMed38225729

2024

Tensile Stress-Activated and Exosome-Transferred YAP/TAZ-Notch Circuit Specifies Type H Endothelial Cell for Segmental Bone Regeneration.

Applications

Unspecified application

Species

Unspecified reactive species

Feng Wang,Shanyu Li,Lingchi Kong,Kai Feng,Rongtai Zuo,Hanzhe Zhang,Yifan Yu,Kunqi Zhang,Yuting Cao,Yimin Chai,Qinglin Kang,Jia Xu

View all publications

style

left-column

style

left-column

style

right-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。

保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-Tafazzin/TAZ 抗体 [EPR26956-58]

Anti-Tafazzin/TAZ antibody [EPR26956-58]

Immunoprecipitation - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)

Western blot - Anti-Tafazzin/TAZ antibody [EPR26956-58] (AB307148)

関連する標識済み抗体及び組成の異なる製品 (1)

Key facts

宿主種

クローン性

クローン番号

アイソタイプ

キャリアフリー

交差種

アプリケーション

免疫原

組合せ製品

Reagents, Controls & Accessories

Primary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity data

製品の詳細

出荷温度及び保存条件

製品の状態

精製方法

バッファー組成

出荷温度

短期保存期間

短期保存温度

長期保存温度

分注に関する情報

保管に関する情報

補足情報

Biological function summary

Pathways

製品プロトコール

ターゲットの情報

文献 (3)

Abcam product promise